(Date:11/30/2009)...KLAND, Mass., Nov. 30 EMD Serono, ...nounced today that it received a refuse to file le...) on the New Drug Application (NDA) for Cladribine... oral formulation of cladribine, as a therapy for ... "The company will work closely with the FDA to fu...
(Date:11/30/2009)...AZOO, Mich., Nov. 30 Str...definitive agreement to acquire privately held As...in the reprocessing and remanufacturing of medical... agreement, Stryker will acquire Ascent Healthcare...tion. The closing is conditioned on the expiration...
(Date:11/30/2009)... rise to more women having babies later in life,...- A growing number of children in the United State...rchers say. , The overriding reason, experts ad..., Data from 10 regional registries of birth defect....S. children increased by 31 percent between 1979 ...
(Date:11/30/2009)... APR Energy (APR) recently donated medicin... Esperanza during a Free General Health Campaign c...nza, Caja Municipal and Huggies. The donation was ...ommunities where they build, own and operate plant...argeted at benefiting the areas surrounding APR,s ...
(Date:11/30/2009)... To best serve our patients, their caregiv...th the Institute of Women,s Health of North Americ...ation. This service is available to all individual...t our website to locate a convenient LOCATION ne... (Vocus) November 30, 2009 -- According to ...
Breaking Medicine News(10 mins):Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 2Health News:EMD Serono Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application 3Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 2Health News:Stryker Announces Definitive Agreement To Acquire Ascent Healthcare Solutions 3Health News:U.S. Records Increase in Kids With Down Syndrome 2Health News:U.S. Records Increase in Kids With Down Syndrome 3Health News:APR Energy Donates Medicine and Medical Services to Community of La Esperanza 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 2Health News:2009 H1N1 Influenza Vaccination Being Offered at Various Affiliated Campuses of the Institute of Women's Health of North America in Florida 3...RNewswire-FirstCall/ - IMRIS Inc. (TSX: IM) ("IMRI...iversity Huashan Hospital in Shanghai, China has s... department. Huashan Hospital will be the first in...dure without moving the patient. The project inclu...
...THAT ASTHMA PATIENTS WHO STOP USING ASTHMA CONTROL... , WASHINGTON , April 15 A new nationwide tel...ost asthma patients know the risks of "uncontrolle...s are not present. Data from The Asthma G.A.P. ...
...andards for First National Measures of Hospital Ef...art Angioplasty, and Pneumonia , , Detailed Hospi...group.org/cp , , WASHINGTON, April 15 Though it...ospitals still have failed to implement standards ...
... 15 Baptist Memorial Health Care Corp. em... phase of the "Our House is Your House" capital ca...emmons Wilson Family Center for Good Grief as they...g out to their colleagues to make donations. , , ...
...d NEW YORK, April 15 HLTH Corporation (Nasdaq: ... WebMD Health Corp. (Nasdaq: WBMD ), today annou...cial results for the three months ended March 31, ...ults. , , Investors can access the call via web...
...f endoscopic ultrasound (EUS) examination is its l... lesion. The differential diagnosis between benign...sses based on the EUS appearance is difficult and ...chnique that can be applied during ultrasound (US)...
Other Medicine News:Health News:National Survey Reveals Gap in 'Uncontrolled Asthma' Knowledge - Putting Asthma Patients at Risk for Serious Health Consequences 2Health News:National Survey Reveals Gap in 'Uncontrolled Asthma' Knowledge - Putting Asthma Patients at Risk for Serious Health Consequences 3Health News:National Survey Reveals Gap in 'Uncontrolled Asthma' Knowledge - Putting Asthma Patients at Risk for Serious Health Consequences 4Health News:Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards 2Health News:Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards 3Health News:Leapfrog Group Hospital Survey Finds Majority of Hospitals Fail to Meet Important Quality Standards 4Health News:Baptist Colleagues Raise $1 Million for Baptist Trinity Hospice House and Kemmons Wilson Family Center for Good Grief 2Health News:HLTH and WebMD Announce First Quarter Earnings Release Date and Conference Call 2Health News:Can EUS elastography help distinguish benign from malignant tissue? 2(Date:11/30/2009)... Va., Nov. 30 Intelliject, Inc. to...ntis U.S. for a novel epinephrine auto-injector, i..., sanofi-aventis U.S. shall be responsible for man... be responsible for the on-going development and f...ined certain co-promotion rights in the territory....
(Date:11/30/2009)... OAKS, Calif., Nov. 30 A... will present updated long-term safety and efficac...onic immune (idiopathic) thrombocytopenic purpura ...Nplate study in a pediatric setting as well as in ...he 2009 American Society of Hematology (ASH) Annua...
(Date:11/30/2009)... November 30 , ... the European Union in,the Last 10 Years , ...announced today that the,European Commission has g...edarone - 400mg Tablets) in all 27 European member...sion positive opinion issued on September 25, 2009...
Breaking Medicine Technology:Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 2Intelliject, Inc. Enters Into Licensing Agreement with sanofi-aventis for U.S./Canada Rights to Novel Epinephrine Auto-injector 3Amgen Highlights Data to be Presented at ASH 2Amgen Highlights Data to be Presented at ASH 3Amgen Highlights Data to be Presented at ASH 4Amgen Highlights Data to be Presented at ASH 5Amgen Highlights Data to be Presented at ASH 6Amgen Highlights Data to be Presented at ASH 7Amgen Highlights Data to be Presented at ASH 8Amgen Highlights Data to be Presented at ASH 9Amgen Highlights Data to be Presented at ASH 10Amgen Highlights Data to be Presented at ASH 11Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 2Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 3Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 4Sanofi-aventis: Multaq(R) Approved in the European Union for Patients With Atrial Fibrillation 5Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 1Insmed Announces Addition to the Russell 3000 28R 29 Index 12842 2Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic CXA 101 in Patients with Complicated Urinary Tract Infections 4668 1Calixa Therapeutics Announces Initiation of Phase 2 Clinical Trial of Its Antibiotic CXA 101 in Patients with Complicated Urinary Tract Infections 4668 2Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market 50365 1Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market 50365 2Growing Proteomics Market and the Current Economic Crisis Could Act in Tandem to Spur Growth in the European 2 Dimensional Gel Electrophoresis Market 50365 3...o;In anaplastic,astrocytoma, AP 12009 as a monothe...” Prof. Albert Wong, M.D., Stanford,Universi...nal Phase,IIb study with the TGF-beta 2-inhibitor ...rof. Wong discussed the results of the study,in th...tem tumors,at the 43rd Annual Meeting of the Ameri...
...and When , Data from the PROactive and CHICAGO stu...ted in poster format at the 67th,Scientific Sessio...: , , -- Hospitalizations for serious adverse e...s treated with pioglitazone for 3 years: results f...Saturday, June 23, from 12:30-, 2:30 p.m. a...
Other Medicine Technology:Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 2Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 3Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma 4MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 2MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating,MacroVascular Outcomes Presented at the American Diabetes,Association 67th Scientific Sessions 3Ascent Primary Knee System - Ascent/Maxim primary interlok tibial trays
...the "Consensus Concept" approach to design by comb... experience of a Scientific Advisory Board. The re...s state-of-the-art features. Consensus Knee implan...stability and allow near normal kinematics. The co...
NexGen Complete Knee Solution Legacy Knee Posterior Stabilized (LPS)
LCS Complete Mobile-Bearing Knee System
Medicine Products: